Further studies on larger groups of patients are required to confirm our suggested potential benefits when it comes to using measurements of plasma concentrations of adiponectin and resistin as biochemical markers of cardiac dysfunction and remodelling in the monitoring of patients with CAD. The gene discussed is ADIPOQ; the disease is coronary artery disorder.